tradingkey.logo
tradingkey.logo
Search

InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

ReutersMay 13, 2026 11:50 AM
facebooktwitterlinkedin
View all comments0

- InnoCare Pharma Ltd 688428.SS:

  • INNOCARE ANNOUNCE FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF ICP-054, A NOVEL POTENTIALLY BEST-IN-CLASS ORAL IL-17AA/AF INHIBITOR

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI